Emerging evidence supports whole-brain radiation therapy (WBRT) and epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib, and afatinib, for NSCLC patients affected by brain metastasis [7,8]. Here, EGFR is linked to non-small cell lung carcinoma.